1. Home
  2. CAPS vs KPRX Comparison

CAPS vs KPRX Comparison

Compare CAPS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPS
  • KPRX
  • Stock Information
  • Founded
  • CAPS 1987
  • KPRX 1998
  • Country
  • CAPS United States
  • KPRX United States
  • Employees
  • CAPS N/A
  • KPRX N/A
  • Industry
  • CAPS
  • KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • CAPS
  • KPRX Health Care
  • Exchange
  • CAPS NYSE
  • KPRX Nasdaq
  • Market Cap
  • CAPS 7.4M
  • KPRX 8.6M
  • IPO Year
  • CAPS N/A
  • KPRX N/A
  • Fundamental
  • Price
  • CAPS $1.60
  • KPRX $2.99
  • Analyst Decision
  • CAPS
  • KPRX Strong Buy
  • Analyst Count
  • CAPS 0
  • KPRX 1
  • Target Price
  • CAPS N/A
  • KPRX $10.00
  • AVG Volume (30 Days)
  • CAPS 93.7K
  • KPRX 61.8K
  • Earning Date
  • CAPS 04-02-2025
  • KPRX 08-08-2025
  • Dividend Yield
  • CAPS N/A
  • KPRX N/A
  • EPS Growth
  • CAPS N/A
  • KPRX N/A
  • EPS
  • CAPS N/A
  • KPRX N/A
  • Revenue
  • CAPS $43,416,000.00
  • KPRX $20,000.00
  • Revenue This Year
  • CAPS $7.87
  • KPRX N/A
  • Revenue Next Year
  • CAPS N/A
  • KPRX N/A
  • P/E Ratio
  • CAPS N/A
  • KPRX N/A
  • Revenue Growth
  • CAPS N/A
  • KPRX N/A
  • 52 Week Low
  • CAPS $1.30
  • KPRX $2.51
  • 52 Week High
  • CAPS $16.18
  • KPRX $4.80
  • Technical
  • Relative Strength Index (RSI)
  • CAPS N/A
  • KPRX 47.28
  • Support Level
  • CAPS N/A
  • KPRX $2.96
  • Resistance Level
  • CAPS N/A
  • KPRX $3.29
  • Average True Range (ATR)
  • CAPS 0.00
  • KPRX 0.15
  • MACD
  • CAPS 0.00
  • KPRX 0.01
  • Stochastic Oscillator
  • CAPS 0.00
  • KPRX 38.78

About CAPS CAPSTONE HOLDING CORP

Capstone Holding Corp is a building products distribution network. The existing network is comprised of Instone, a distributor of thin veneer stone and related masonry products in the United States, serving both residential and commercial construction markets. The company's product offering includes manufactured and natural stone products, supported by a distribution network. The company's current products include stone veneer, landscape stone, and modular masonry fireplaces.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: